Greenwich LifeSciences (GLSI)
Runs a single Phase III trial for a peptide vaccine preventing HER2-positive breast cancer recurrence.
$15.81
Pre-market+0.02 (+0.13%)
At close$15.79(+5.20%)
Something off on this page? Send us feedback.
Breakdown13F · 13D/G · Form 4
| Institutions63 holders · as of Mar 31, 2026 | 11.67% | 1.71M shares | |
| Insiders4 holders · as of Jul 30, 2026 | 78.15% | 11.47M shares | |
| Otherremainder | 10.18% | 1.49M shares |
14.68M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Institutions13F, as of Mar 31, 2026
63 holders · 1.71M shares · 25 new positions · 42 increased · 11 reduced · 11 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 433.9K | 2.96% | +62.4K | May 13, 2026 |
| Vanguard Capital Management LLC | 298.3K | 2.03% | +298.3Knew | May 15, 2026 |
| Geode Capital Management, LLC | 155.5K | 1.06% | +3.8K | May 15, 2026 |
| State Street Corp | 133.9K | 0.91% | +36.1K | May 15, 2026 |
| Nuveen, LLC | 88.7K | 0.60% | +88.7Knew | Apr 30, 2026 |
| Northern Trust Corp | 75.1K | 0.51% | +2.1K | May 14, 2026 |
| Vanguard Portfolio Management LLC | 58.9K | 0.40% | +58.9Knew | May 8, 2026 |
| Bank of New York Mellon Corp | 46.5K | 0.32% | +32.7K | May 5, 2026 |
Ownership statements13D/G · 5% or more, as filed
No 13D/G filer at 5% or more on record.
Insider tradesForm 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Jul 28, 2026 | Snehal Pateldirector, 10 percent owner, officer: CEO and CFO | Purchase | 1,500 | $13.59 | 5,610,702 |
| Jul 29, 2026 | Snehal Pateldirector, 10 percent owner, officer: CEO and CFO | Purchase | 700 | $13.10 | 5,611,402 |
| Jul 27, 2026 | Snehal Pateldirector, 10 percent owner, officer: CEO and CFO | Purchase | 1,500 | $13.62 | 5,609,202 |
| Jul 23, 2026 | Snehal Pateldirector, 10 percent owner, officer: CEO and CFO | Purchase | 2,500 | $13.14 | 5,606,602 |
| Jul 24, 2026 | Snehal Pateldirector, 10 percent owner, officer: CEO and CFO | Purchase | 1,100 | $12.88 | 5,607,702 |
| Jan 13, 2026 | Snehal Pateldirector, 10 percent owner, officer: CEO and CFO | Purchase | 1,800 | $29.83 | 5,604,102 |
| Jan 12, 2026 | Snehal Pateldirector, 10 percent owner, officer: CEO and CFO | Purchase | 2,900 | $27.54 | 5,602,302 |
| Dec 31, 2025 | Snehal Pateldirector, 10 percent owner, officer: CEO and CFO | Purchase | 4,300 | $21.36 | 5,599,402 |
| Dec 30, 2025 | Snehal Pateldirector, 10 percent owner, officer: CEO and CFO | Purchase | 2,900 | $21.73 | 5,595,102 |
| Dec 18, 2025 | Snehal Pateldirector, 10 percent owner, officer: CEO and CFO | Purchase | 4,100 | $12.62 | 5,592,202 |
CongressHouse and Senate disclosures
Not reported.